Sigma-Tau Pharmaceuticals Announces First Patient Dosed In Phase 1/2 Clinical Trial Of STP206 For Prevention Of Necrotizing Enterocolitis In Very Low Birth Weight Premature Infants

Published: Feb 04, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GAITHERSBURG, Md., Feb. 4, 2014 (GLOBE NEWSWIRE) -- Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) today announced that the first patient has been dosed as part of the Company's Phase I/II multi-center, double-blind, randomized, placebo-controlled clinical trial for STP206, in development for the prevention of necrotizing enterocolitis (NEC) in very low birth weight premature infants. STP206 is a live biotherapeutic being developed in the United States, under an FDA investigational new drug application (IND).

Help employers find you! Check out all the jobs and post your resume.

Back to news